Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:BGXXNASDAQ:ERNANASDAQ:GRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.08-1.9%$2.25$1.63▼$4.66$10.77M0.82262,582 shs37,800 shsBGXXBright Green$0.05$0.03▼$0.54$11.47M-0.26360,154 shs25,935 shsERNAErnexa Therapeutics$2.45-6.8%$3.00$2.08▼$39.38$18.04M5.55193,657 shs37,801 shsGRIGRI Bio$1.32-5.7%$1.51$1.10▼$59.33$2.83M-1.68116,154 shs110,623 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia0.00%-4.59%+9.47%-21.80%-41.24%BGXXBright Green0.00%0.00%0.00%+39.53%-78.28%ERNAErnexa Therapeutics0.00%+6.99%-28.49%-38.25%-91.60%GRIGRI Bio0.00%+1.54%+5.60%-84.04%-97.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.5241 of 5 stars3.85.00.00.02.22.50.6BGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/AERNAErnexa Therapeutics1.2135 of 5 stars0.05.00.00.02.81.70.0GRIGRI Bio1.954 of 5 stars3.52.00.00.01.40.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,101.92% UpsideBGXXBright Green 0.00N/AN/AN/AERNAErnexa Therapeutics 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,566.67% UpsideCurrent Analyst Ratings BreakdownLatest GRI, ERNA, BCDA, and BGXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K179.57N/AN/A$0.18 per share11.56BGXXBright GreenN/AN/AN/AN/A$0.06 per shareN/AERNAErnexa Therapeutics$580K31.09N/AN/A$0.50 per share4.90GRIGRI BioN/AN/AN/AN/A$7.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)BGXXBright Green-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/AERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-285.71%8/11/2025 (Estimated)GRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)Latest GRI, ERNA, BCDA, and BGXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ABGXXBright GreenN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36BGXXBright GreenN/A0.010.01ERNAErnexa TherapeuticsN/A0.210.21GRIGRI BioN/A1.411.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%BGXXBright Green7.83%ERNAErnexa Therapeutics70.55%GRIGRI Bio33.95%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%BGXXBright Green62.55%ERNAErnexa Therapeutics1.50%GRIGRI Bio0.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million4.14 millionOptionableBGXXBright Green2191.17 million71.59 millionNo DataERNAErnexa Therapeutics107.36 million7.26 millionNo DataGRIGRI Bio12.14 million2.14 millionNot OptionableGRI, ERNA, BCDA, and BGXX HeadlinesRecent News About These CompaniesQ2 Earnings Forecast for GRI Bio Issued By HC WainwrightJune 15, 2025 | americanbankingnews.comKalkine : GRI Bio Advancing in the Nasdaq Composite Healthcare SpaceJune 13, 2025 | kalkinemedia.comGRI Bio (NASDAQ:GRI) Given "Buy" Rating at HC WainwrightJune 13, 2025 | americanbankingnews.comGRI Bio Analyst Ratings and Price Targets | NASDAQ:GRI | BenzingaMay 29, 2025 | benzinga.comGRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase ...May 24, 2025 | morningstar.comGRI Bio reports progress in pulmonary fibrosis treatmentMay 24, 2025 | investing.comGRI Bio Expands Share Offering AgreementMay 23, 2025 | tipranks.comGRI Bio to Participate in the Virtual Investor Closing Bell SeriesMay 21, 2025 | globenewswire.comGRI Bio meets interim clinical trial enrollment goal for IPF therapyMay 17, 2025 | pulmonaryfibrosisnews.comGRI Bio, Inc. CEO Marc Hertz to Participate in Live Webcast Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025May 16, 2025 | quiverquant.comGRI Bio to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 16, 2025 | globenewswire.comGRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025May 15, 2025 | globenewswire.comGRI Bio reports positive interim biomarker data in IPF studyMay 10, 2025 | uk.investing.comGRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)May 8, 2025 | globenewswire.comGRI Bio, Inc.: GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")May 8, 2025 | finanznachrichten.deGRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)May 7, 2025 | globenewswire.comGRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International ConferenceApril 16, 2025 | globenewswire.comGRI Bio Announces $5 Million Public Offering Amid Market DeclineApril 3, 2025 | nasdaq.comGRI Bio Announces Closing of $5.0 Million Public OfferingApril 2, 2025 | globenewswire.comGRI Stock Down on Public Offering Despite Encouraging IPF Study DataApril 2, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsGRI, ERNA, BCDA, and BGXX Company DescriptionsBioCardia NASDAQ:BCDA$2.08 -0.04 (-1.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.21 +0.13 (+6.25%) As of 06/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Bright Green NASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.Ernexa Therapeutics NASDAQ:ERNA$2.45 -0.18 (-6.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.53 +0.08 (+3.43%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.GRI Bio NASDAQ:GRI$1.32 -0.08 (-5.71%) As of 06/20/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
